139 related articles for article (PubMed ID: 38097389)
1. Dupilumab-induced psoriasiform dermatitis in two pediatric cardiac transplant patients.
Lockard T; Mullen SA; Lee EB; Niebur H; Harter N
Pediatr Dermatol; 2024; 41(3):508-511. PubMed ID: 38097389
[TBL] [Abstract][Full Text] [Related]
2. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.
Parker JJ; Sugarman JL; Silverberg NB; Gonzalez ME; Ramien ML; Teng JMC; Paller AS
Pediatr Dermatol; 2021 Nov; 38(6):1500-1505. PubMed ID: 34647354
[TBL] [Abstract][Full Text] [Related]
3. A pediatric case of dupilumab-induced pustular psoriasis.
Dang N; Zheng H; Ren Y
J Dermatolog Treat; 2024 Dec; 35(1):2333016. PubMed ID: 38839072
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab-Associated Psoriasis and Psoriasiform Manifestations: A Scoping Review.
Su Z; Zeng YP
Dermatology; 2023; 239(4):646-657. PubMed ID: 37100035
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab-associated psoriasis and psoriasiform dermatitis in patients with atopic dermatitis.
Casale F; Nguyen C; Dobry A; Smith J; Mesinkovska NA
Australas J Dermatol; 2022 Aug; 63(3):394-397. PubMed ID: 35460570
[No Abstract] [Full Text] [Related]
6. The use of selective Th2 blocker dupilumab for the treatment of atopic dermatitis in a heart transplant patient: Case report.
Sklover L; Nielson C; De Benedetto A
Dermatol Ther; 2019 Nov; 32(6):e13144. PubMed ID: 31664753
[TBL] [Abstract][Full Text] [Related]
7. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.
Gori N; Chiricozzi A; Malvaso D; D'Urso DF; Caldarola G; De Simone C; Peris K
Dermatology; 2021; 237(4):535-541. PubMed ID: 33477153
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report.
Ludriksone L; Elsner P; Malessa C; Settmacher U; Schliemann S
J Dtsch Dermatol Ges; 2020 Jul; 18(7):740-742. PubMed ID: 32212242
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of dupilumab for atopic dermatitis in a renal transplant patient.
Randriamiarana T; Boutin D; Thierry A; Lecron JC; Hainaut E; Masson Regnault M
Ann Dermatol Venereol; 2024 Jun; 151(2):103259. PubMed ID: 38507958
[No Abstract] [Full Text] [Related]
10. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: A case series.
Napolitano M; Scalvenzi M; Fabbrocini G; Cinelli E; Patruno C
Dermatol Ther; 2019 Nov; 32(6):e13142. PubMed ID: 31664761
[No Abstract] [Full Text] [Related]
12. Pustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis.
Jia X; Li C; Wu J; Liu Q
J Drugs Dermatol; 2022 Mar; 21(3):311-312. PubMed ID: 35254760
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.
Ariëns LFM; van der Schaft J; Spekhorst LS; Bakker DS; Romeijn GLE; Kouwenhoven TA; Kamsteeg M; Voorberg AN; Oosting AJ; de Ridder I; Sloeserwij A; Haeck I; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
J Am Acad Dermatol; 2021 Apr; 84(4):1000-1009. PubMed ID: 32946967
[TBL] [Abstract][Full Text] [Related]
14. Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis.
Ludwig CM; Hsiao JL; Lio PA; Shi VY
Dermatitis; 2021 Oct; 32(1S):S4-S7. PubMed ID: 33273236
[TBL] [Abstract][Full Text] [Related]
15. Severe atopic dermatitis: Dupilumab is not just safer, but more efficient.
Giavina-Bianchi M; Rizzo LV; Giavina-Bianchi P
Allergol Immunopathol (Madr); 2020; 48(6):792-797. PubMed ID: 32249095
[TBL] [Abstract][Full Text] [Related]
16. Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
Kurihara K; Fujiyama T; Tokura Y; Honda T
Eur J Dermatol; 2021 Oct; 31(5):658-660. PubMed ID: 34704949
[No Abstract] [Full Text] [Related]
17. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment.
Napolitano M; Caiazzo G; Fabbrocini G; Balato A; Di Caprio R; Scala E; Scalvenzi M; Patruno C
Br J Dermatol; 2021 Feb; 184(2):341-343. PubMed ID: 33533476
[No Abstract] [Full Text] [Related]
19. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
[TBL] [Abstract][Full Text] [Related]
20. Dupixent® (Dupilumab): A Newly Approved Interleukin-4 Receptor Antagonist for the Treatment of Atopic Dermatitis in Pediatric Patients.
Gupta AK; Love RP; Abramovits W; Vincent KD
Skinmed; 2019; 17(2):107-109. PubMed ID: 31145061
[No Abstract] [Full Text] [Related]
[Next] [New Search]
